Dotinurad (BioDeep_00000839766)
代谢物信息卡片
Dotinurad
化学式: C14H9Cl2NO4S (356.96293340000005)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl
InChI: InChI=1S/C14H9Cl2NO4S/c15-9-5-8(6-10(16)13(9)18)14(19)17-7-22(20,21)12-4-2-1-3-11(12)17/h1-6,18H,7H2
描述信息
D018501 - Antirheumatic Agents > D006074 - Gout Suppressants > D014528 - Uricosuric Agents
C26170 - Protective Agent > C921 - Uricosuric Agent
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Sakura Iida, Hisayuki Katsuyama. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease.
Cells.
2024 Mar; 13(5):. doi:
10.3390/cells13050450. [PMID: 38474414] - Young Ho Lee, Gwan Gyu Song. Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
International journal of clinical pharmacology and therapeutics.
2022 Mar; 60(3):159-166. doi:
10.5414/cp204097. [PMID: 34779393] - Toshinari Takahashi, Takanobu Beppu, Yuji Hidaka, Tatsuo Hosoya. Comparative study of a novel selective urate reabsorption inhibitor 'dotinurad' among patient groups with different stages of renal dysfunction.
Clinical and experimental nephrology.
2021 Dec; 25(12):1336-1345. doi:
10.1007/s10157-021-02115-7. [PMID: 34328574] - Toshinari Takahashi, Takanobu Beppu, Yuji Hidaka, Tatsuo Hosoya. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
Clinical and experimental hypertension (New York, N.Y. : 1993).
2021 Nov; 43(8):730-741. doi:
10.1080/10641963.2021.1950752. [PMID: 34425059] - Koichi Omura, Keisuke Motoki, Seiichi Kobashi, Kengo Miyata, Katsuhiro Yamano, Takashi Iwanaga. Identification of Human UDP-Glucuronosyltransferase and Sulfotransferase as Responsible for the Metabolism of Dotinurad, a Novel Selective Urate Reabsorption Inhibitor.
Drug metabolism and disposition: the biological fate of chemicals.
2021 11; 49(11):1016-1024. doi:
10.1124/dmd.120.000251. [PMID: 34380635] - Tomohiko Ishikawa, Toshinari Takahashi, Tetsuya Taniguchi, Tatsuo Hosoya. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Expert opinion on pharmacotherapy.
2021 Aug; 22(11):1397-1406. doi:
10.1080/14656566.2021.1918102. [PMID: 33926357] - Junichiro Uda, Seiichi Kobashi, Naoki Ashizawa, Koji Matsumoto, Takashi Iwanaga. Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity.
Bioorganic & medicinal chemistry letters.
2021 05; 40(?):127900. doi:
10.1016/j.bmcl.2021.127900. [PMID: 33684442] - Koichi Omura, Kengo Miyata, Seiichi Kobashi, Azusa Ito, Masahiko Fushimi, Junichiro Uda, Tomomitsu Sasaki, Takashi Iwanaga, Tetsuo Ohashi. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor.
Drug metabolism and pharmacokinetics.
2020 Jun; 35(3):313-320. doi:
10.1016/j.dmpk.2020.03.002. [PMID: 32327267] - Yuji Kumagai, Masashi Sakaki, Kenichi Furihata, Takayoshi Ito, Kazuaki Inoue, Takafumi Yoshida, Shigeki Matsumoto, Kazuki Furuno, Atsushi Hagino. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):25-35. doi:
10.1007/s10157-019-01816-4. [PMID: 31760530] - Kenichi Furihata, Katsuaki Nagasawa, Atsushi Hagino, Yuji Kumagai. A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):36-43. doi:
10.1007/s10157-020-01855-2. [PMID: 32076889] - Hiroyuki Fukase, Daisuke Okui, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi, Tatsuo Hosoya. Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):17-24. doi:
10.1007/s10157-019-01825-3. [PMID: 31823130] - Hiroshi Nakatani, Masahiko Fushimi, Tomomitsu Sasaki, Daisuke Okui, Tetsuo Ohashi. Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):8-16. doi:
10.1007/s10157-019-01836-0. [PMID: 31889230] - Tatsuo Hosoya, Takafumi Sano, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):53-61. doi:
10.1007/s10157-019-01818-2. [PMID: 31792640] - Tatsuo Hosoya, Takafumi Sano, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):44-52. doi:
10.1007/s10157-019-01802-w. [PMID: 31754882] - Tatsuo Hosoya, Masahiko Fushimi, Daisuke Okui, Tomomitsu Sasaki, Tetsuo Ohashi. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):80-91. doi:
10.1007/s10157-019-01831-5. [PMID: 31875931] - Tatsuo Hosoya, Takafumi Sano, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):62-70. doi:
10.1007/s10157-020-01849-0. [PMID: 31980978] - Tatsuo Hosoya, Kazuki Furuno, Shingo Kanda. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):71-79. doi:
10.1007/s10157-020-01851-6. [PMID: 31970593] - Daisuke Okui, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):92-102. doi:
10.1007/s10157-019-01817-3. [PMID: 31734820] - Satoru Kuriyama. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):1-5. doi:
10.1007/s10157-019-01811-9. [PMID: 31754883] - Tatsuo Hosoya, Kazuki Furuno, Shingo Kanda. A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):103-111. doi:
10.1007/s10157-020-01857-0. [PMID: 32067130] - Hiroshi Arakawa, Natsumi Amezawa, Yu Kawakatsu, Ikumi Tamai. Renal Reabsorptive Transport of Uric Acid Precursor Xanthine by URAT1 and GLUT9.
Biological & pharmaceutical bulletin.
2020; 43(11):1792-1798. doi:
10.1248/bpb.b20-00597. [PMID: 33132325] - Keisuke Motoki, Takako Igarashi, Koichi Omura, Hiroshi Nakatani, Takashi Iwanaga, Ikumi Tamai, Tetsuo Ohashi. Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers.
Pharmacology research & perspectives.
2019 12; 7(6):e00533. doi:
10.1002/prp2.533. [PMID: 31788318] - Tetsuya Taniguchi, Naoki Ashizawa, Koji Matsumoto, Ryo Saito, Keisuke Motoki, Miku Sakai, Noriko Chikamatsu, Chiharu Hagihara, Masamichi Hashiba, Takashi Iwanaga. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
The Journal of pharmacology and experimental therapeutics.
2019 10; 371(1):162-170. doi:
10.1124/jpet.119.259341. [PMID: 31371478] - Xinrui Li, Jing Liu, Liang Ma, Ping Fu. Pharmacological urate-lowering approaches in chronic kidney disease.
European journal of medicinal chemistry.
2019 Mar; 166(?):186-196. doi:
10.1016/j.ejmech.2019.01.043. [PMID: 30769179]